| Name | Title | Contact Details |
|---|
Cartessa Aesthetics is a progressive company focused on sourcing, distributing, and supporting class-leading technology to plastic surgeons, dermatologists, physicians and medical spas.
We hold market leading positions in advanced wound care, ostomy care, continence and critical care and infusion devices. Our customers depend on our advanced technologies to help reduce potential complications of skin breakdown and infection, and they rely on our products and services to help manage their conditions every day. Meeting their needs is what motivates us and is a source of tremendous pride for our nearly 9,500 employees who are based in more than 110 countries worldwide. At ConvaTec, we exist to improve the lives of the people we touch. We are committed to helping people with chronic health conditions lead the life they want – giving them more mobility, confidence and freedom. Our vision is to be recognised as the most respected and successful MedTech company, worldwide. To achieve this, we drive for excellence in all that we do – anticipating and addressing our customers` needs with advanced technologies and best-in-class products and services. Our values-based culture helps drive our success. Caring for People: We are passionate about improving people`s lives and put people at the centre of everything we do. Driving Innovation and Excellence: We are dedicated to finding innovative solutions that anticipate and address our customers` needs and to delivering best-in-class execution. Earning Trust: We earn trust by delivering quality products and services that our customers can rely on. Our personal actions underpin this trust – we do what we say we will do.
Sechrist Industries Inc is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.
ValenTx was founded with the goal of treating some of the most pervasive health problems of our time: obesity and obesity-related metabolic disorders such as type-2 diabetes and hypertension. Our approach is to create a non-surgical, endoluminal bypass device that builds on the success of established medical interventions, resulting in a highly effective and least-invasive therapy. Current treatments for these diseases include surgery, pharmacology, and medically supervised lifestyle management. The risks, costs, and in some cases poor efficacy of these treatments have hampered their broad adoption by patients, physicians, and payers alike. A truly unmet clinical need exists for a therapy that can deliver the efficacy obtained through surgery, but without the risks and costs associated with surgical intervention. The ValenTx endoluminal bypass therapy mimics the attributes of a Roux-en-Y gastric bypass and is implanted through a non-surgical, endoscopic procedure. This procedure does not require gastric stapling or permanent changes to the patient`s anatomy. The device is removable, replaceable and designed so that the physician could change the therapeutic profile, thereby optimizing the treatment towards the individual patient`s needs. ValenTx has developed a strong intellectual property portfolio, which lies at the foundation of this therapy. The company has successfully conducted a series of clinical studies demonstrating the viability, safety, and efficacy of the therapy.
Pulse Biosciences is a novel medical therapy company bringing to market its proprietary CellFX™ Nano-Pulse Stimulation™ (NPS™) platform. The Company`s CellFX NPS platform provides a novel, precise, non-thermal, treatment technology delivering nanosecond duration energy pulses that impact cells in treated tissue while sparing acellular tissue. NPS`s unique mechanism of action disrupts the functions of internal cell structures while maintaining the outer cell membrane initiating a cascade of events within the cell that results in regulated cell death.